Clinical trials: Acute Psychosis
Schizophrenia
Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension
This is the long-term open label extension (OLE) of the study PRISMA-3 (NCT03160521). Those patients who complete participation in the main segment of the study (double blind) together with other clinically stable not previously…
- Trial name
- PRISMA-3_OLE (NCT03870880)
- Testing
- Risperidone ISM 75 mg, Risperidone ISM 100 mg
- Where
- 24 sites in United States, Ukraine
- Volunteers
- 215 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Inflammatory Bowel Diseases, Depressive Episode
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the impacts on quality-of-life outcomes and use of healthcare services in people aged 5 - 25 years…
- Conditions
- Inflammatory Bowel Diseases, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorder
- Trial name
- NCT05206734
- Testing
- No specific intervention
- Where
- United Kingdom
- Volunteers
- 19,469 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Schizophrenia
Study of Efficacy and Safety of Seroquel (Quetiapine Fumarate) as Mono-Therapy for Acute Schizophrenic
The primary objective of the study is to evaluate the efficacy of quetiapine fumarate (Seroquel) with daily dose 600mg-750mg used as mono-therapy in the treatment of acute schizophrenic patients by evaluation of the change from…
- Trial name
- NCT00428350
- Testing
- Quetiapine Fumarate (Seroquel)
- Where
- 9 sites in China
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Schizophrenia
Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients
The primary objective of this study is to evaluate the efficacy of quetiapine fumarate extended-release (XR) used as mono-therapy, administered once daily, in the treatment of schizophrenic patient with acute episode.
- Trial name
- ESPRIT (NCT00882518)
- Testing
- Quetiapine Fumarate (SEROQUEL) Extended-Release (XR), Chlorpromazine
- Where
- 11 sites in China
- Volunteers
- 388 people
- Sponsor
- AstraZeneca
Schizophrenia
Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia
Over recent years an approach with the adjunctive administration of various anticonvulsant drugs has been discussed and a limited number of open and controlled studies were performed for carbamazepine, valproic acid, and…
- Trial name
- OXC-SCZ (NCT00637234)
- Testing
- Oxcarbazepine
- Where
- 2 sites in Germany
- Volunteers
- 54 people
- Sponsor
- University of Cologne
Schizophrenia, Schizotypal Disorder
The OPUS YOUNG Trial. Early Intervention Versus Treatment as Usual for Adolescents With First-episode Psychosis
The OPUS YOUNG (OY) study investigates the efficacy of early intervention service versus treatment as usual (TAU) for adolescents aged 12-17 years with a first-episode psychosis.
- Conditions
- Schizophrenia, Schizotypal Disorder, Delusional Disorder, Acute and Transient Psychotic Disorder, Unspecified
- Trial name
- OPUS-YOUNG (NCT04916626)
- Testing
- OPUS YOUNG, Treatment as Usual
- Where
- Denmark
- Volunteers
- 284 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital